Assessment of calcium dobesilate in diabetic retinopathy. A double-blind clinical investigation.
In this double-blind, randomized trial, which lasted for 2 years, the authors investigated the efficacy of calcium dobesilate on diabetic retinopathy. 68 patients (51 on the active substance, 17 on placebo) participated in the study. The statistical analysis of the results indicate that calcium dobesilate acts as a potent angioprotector, capable of preventing both intra and extraretinal hemorrhages. The drug also lowers the incidence of exudate formation and improves visual acuity.
D001557:Benzenesulfonates / Q000627:therapeutic use*; D002123:Calcium Dobesilate / Q000008:administration & dosage / Q000627:therapeutic use*; D002198:Capillary Fragility / Q000187:drug effects; D002199:Capillary Permeability / Q000187:drug effects; D002986:Clinical Trials as Topic; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D004341:Drug Evaluation; D006801:Humans; D010919:Placebos; D012166:Retinal Hemorrhage / Q000188:drug therapy; D014792:Visual Acuity / Q000187:drug effects
D001557:Benzenesulfonates; D010919:Placebos; D002123:Calcium Dobesilate